Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor

Figure 4 Dihydroergotamine alleviated fibrosis in CCl₄-induced liver fibrosis model mice. A: The width of the portal vein (left panel); portal vein width of mice in each group (right panel, n = 7); B: The velocity of the portal vein (left panel); the velocity of mice in each group (right panel, n = 7); C: Body weight, liver weight, spleen weight, and liver weight/body weight of mice in each group (n = 6-8); D: Gross liver specimens of the mice in each group; E: An automated biochemistry analyzer determined the enzymatic activities of serum levels of alanine aminotransferase and aspartate aminotransferase (n = 6-7); F: Masson’s trichrome staining was performed on liver sections; G: Collagen area in Masson’s trichrome staining (n = 7-8). All data were presented as means ± standard error of the mean. One-way ANOVA test was performed. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, and ^dP < 0.0001. TGFβ: Transforming growth factor β; TGFβR: Transforming growth factor β receptor; DHE: Dihydroergotamine.